Document Detail


Overcoming Cell Death and Tau Phosphorylation Mediated by PI3K-Inhibition: A Cell Assay to Measure Neuroprotection.
MedLine Citation:
PMID:  21222634     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Few targets for neuroprotection have been defined in Alzheimer's disease (AD). Recent data from the role of Wnt, insulin-like growth factor-1 and estradiol pathways in AD suggest some therapeutic targets for disease treatment, and have led us to evaluate the "common factors" in these pathways as further candidate targets. These data have led us to propose that glycogen synthase kinase-3 (GSK-3) inhibition appears to be a common feature of these pathways. Besides, considering that GSK-3 activation seems to be correlated with neurodegeneration, its selection as a relevant target appears obvious. The capacity of different GSK-3 inhibitors to prevent amyloid β-peptide neurotoxicity and tau phosphorylation has been evaluated in order to develop novel clinical and therapeutic approaches. Different approaches could be used to search for new neuroprotective compounds. The most classical of these is to first define the target and then design a specific in vitro screening assay for it. Alternatively, a cell model of cell culture could be used as a "primary screen". Following this rationale, we have used a combined approach in which we first used an in vitro system to select compounds able to inhibit recombinant GSK3β. Subsequently, we subjected the candidate compounds to three consecutive cell-based complementary screening assays. First, cell viability was assessed using a neuroblastoma cell line before assaying the capacity of the compounds to reduce tau phosphorylation. Finally, we designed a neuronal cell model of apoptosis using the phosphatidylinositol kinase-3 inhibitor LY294002. Finally, we summarize several new compounds with "neuroprotective" properties.
Authors:
D Simon; M Medina; J Avila; F Wandosell
Related Documents :
22431524 - Glucose oxidation modulates anoikis and tumor metastasis.
22485174 - In vitro studies on erythrosine-based photodynamic therapy of malignant and pre-maligna...
22642934 - Synergistic/additive interaction of valproic acid with bortezomib on the proliferation ...
7408764 - Effect of thyrotropin on cell orientation and follicle reconstruction in rotated suspen...
3409254 - Interaction of b16 malignant melanoma tumor cells with the murine mesentery in vitro.
15860444 - Beta-sitosterol from psyllium seed husk (plantago ovata forsk) restores gap junctional ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  CNS & neurological disorders drug targets     Volume:  10     ISSN:  1996-3181     ISO Abbreviation:  CNS Neurol Disord Drug Targets     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-01-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101269155     Medline TA:  CNS Neurol Disord Drug Targets     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  208-14     Citation Subset:  IM    
Affiliation:
Centro de Biología Molecular "Severo Ochoa" CIBERNED-CSIC-UAM, C/ Nicolás Cabrera no 1, Cantoblanco, Universidad Autónoma de Madrid; 28049 Madrid, Spain. fwandosell@cbm.uam.es.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Implication of oncogenic signaling pathways as a treatment strategy for neurodegenerative disorders ...
Next Document:  Alzheimer's disease: from pathogenesis to disease-modifying approaches.